Actively Recruiting

Age: 18Years - 80Years
All Genders
NCT06098560

Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients

Led by Geneplus-Beijing Co. Ltd. · Updated on 2025-09-04

60

Participants Needed

2

Research Sites

109 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

dMMR/MSI-H colorectal cancer patients are the dominant population of immunotherapy/neoadjuvant immunotherapy, but imaging evaluation of immunotherapy efficacy is insufficient. There are some cases, although no disease remission was found on imaging,pathological complete response (pCR) was confirmed after surgery. Meanwhile,previous studies have shown that dynamic changes in ctDNA can help assess immunotherapy efficacy. Therefore, we propose to conduct a multicenter, prospective, observational clinical study to explore the efficacy prediction and monitoring value of ctDNA in immunotherapy for advanced or locally advanced dMMR/MSI-H colorectal cancer.

CONDITIONS

Official Title

Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Colorectal Patients

Who Can Participate

Age: 18Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Advanced or locally advanced dMMR/MSI-H colorectal cancer
  • Expected to receive or currently receiving immune checkpoint inhibitor therapy
  • ECOG performance score of 0 or 1
  • Life expectancy of at least 12 weeks
Not Eligible

You will not qualify if you...

  • Presence of other untreated malignancies
  • Serious systemic diseases that impair ability to complete the study
  • Autoimmune disease unsuitable for PD1 monoclonal antibody therapy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Actively Recruiting

2

Fudan University Shanghai Cancer Center

Shanghai, China

Actively Recruiting

Loading map...

Research Team

X

Xiaoyan Zhou, PhD

CONTACT

J

Junjie Peng, PhD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here